Page last updated: 2024-11-02

moxonidine and Obesity

moxonidine has been researched along with Obesity in 22 studies

moxonidine: structure given in first source

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone."9.12The effect of moxonidine on endothelial dysfunction in metabolic syndrome. ( Cikim, AS; Cikim, K; Ozdemir, R; Temel, I; Topal, E, 2006)
"Moxonidine is useful and safe for controlling arterial hypertension in obese patients."9.11Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005)
"To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension."9.09Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999)
" In dose-response experiments, the maximal response (E(max)) was markedly reduced 18."5.34Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007)
"Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism."5.32Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004)
"Twenty-six patients with mild hypertension were treated with moxonidine and a hypocaloric diet for 3 months, while a second normotensive group (n = 26) were followed-up with calorie restriction alone."5.12The effect of moxonidine on endothelial dysfunction in metabolic syndrome. ( Cikim, AS; Cikim, K; Ozdemir, R; Temel, I; Topal, E, 2006)
"Moxonidine is useful and safe for controlling arterial hypertension in obese patients."5.11Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. ( Abellán, J; de Vinuesa, SG; García-Galbis, JA; Hernández-Menárguez, F; Leal, M; Luño, J; Martínez-Pastor, A, 2005)
"To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension."5.09Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. ( Haenni, A; Lithell, H, 1999)
"The I1-imidazoline receptor is a specific high-affinity binding site corresponding to a functional cell-surface receptor mediating the antihypertensive actions of moxonidine and other second-generation centrally-acting agents, and may play a role in countering insulin resistance in an animal model of metabolic syndrome X."4.79The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. ( Ernsberger, P; Friedman, JE; Koletsky, RJ, 1997)
"The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known."3.70The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. ( Bing, C; Brown, M; Kaan, E; King, P; Pickavance, L; Williams, G; Ziegler, D, 1999)
"The sympatholytic antihypertensive agent moxonidine, a centrally acting selective I1-imidazoline receptor modulator (putative agonist), may be beneficial in hypertensive patients with insulin resistance."3.69Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. ( Fogt, DL; Gödicke, J; Henriksen, EJ; Jacob, S; Youngblood, EB, 1997)
"Amlodipine was used as the control drug."2.72Selective imidazoline agonist moxonidine in obese hypertensive patients. ( de Abreu, VG; Francischetti, EA; Sanjuliani, AF, 2006)
"Moxonidine has been shown to improve glucose tolerance in man, probably by two different mechanisms, i."2.40Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. ( Hansson, L, 1998)
" In dose-response experiments, the maximal response (E(max)) was markedly reduced 18."1.34Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. ( Ernsberger, P; Sun, Z, 2007)
" Similar responses were observed after oral dosing and in lean littermates."1.32The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( Ernsberger, P; Velliquette, RA, 2003)
"Using a rat model of metabolic syndrome X, we sought to separate the influence of these two receptors on glucose and lipid metabolism by using selective antagonists."1.32The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( Ernsberger, P; Koletsky, RJ; Velliquette, RA, 2003)
"Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism."1.32Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. ( Marsalek, P; Sharma, AM; Wagner, T, 2004)
"Moxonidine treatment reduced fasting insulin levels by 71% in SHROB and lowered plasma free fatty acids by 25%."1.30Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1999)
"Moxonidine treatment enhanced the expression of IRS-1 protein in skeletal muscle by 74% in SHROB and 40% in SHR."1.30Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1998)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's11 (50.00)18.2507
2000's11 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Velliquette, RA3
Ernsberger, P9
Mukaddam-Daher, S1
Menaouar, A1
El-Ayoubi, R1
Gutkowska, J1
Jankowski, M1
Koletsky, RJ6
Sharma, AM1
Wagner, T1
Marsalek, P1
Abellán, J1
Leal, M1
Hernández-Menárguez, F1
García-Galbis, JA1
Martínez-Pastor, A1
de Vinuesa, SG1
Luño, J1
Sanjuliani, AF1
de Abreu, VG1
Francischetti, EA1
Topal, E1
Cikim, AS1
Cikim, K1
Temel, I1
Ozdemir, R1
Sun, Z1
Kaaja, R1
Kujala, S1
Manhem, K1
Katzman, P1
Kibarskis, A1
Antikainen, R1
Ylihärsilä, H1
Erkkola, R1
Tuomilehto, J1
Kagota, S1
Tada, Y1
Kubota, Y1
Nejime, N1
Yamaguchi, Y1
Nakamura, K1
Kunitomo, M1
Shinozuka, K1
Rupp, H1
Jacob, R1
Collins, LA1
Bedol, D3
Friedman, JE4
Henriksen, EJ1
Jacob, S1
Fogt, DL1
Youngblood, EB1
Gödicke, J1
Ishizuka, T2
Liu, S2
Farrell, CJ2
Hansson, L1
Bing, C1
King, P1
Pickavance, L1
Brown, M1
Ziegler, D1
Kaan, E1
Williams, G1
Haenni, A1
Lithell, H1

Reviews

2 reviews available for moxonidine and Obesity

ArticleYear
The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1997, Volume: 15, Issue:1

    Topics: Animals; Antihypertensive Agents; Binding Sites; Clonidine; Humans; Hypertension; Imidazoles; Imidaz

1997
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.
    Blood pressure. Supplement, 1998, Volume: 3

    Topics: Antihypertensive Agents; Humans; Hyperlipidemias; Hypertension; Imidazoles; Insulin Resistance; Obes

1998

Trials

5 trials available for moxonidine and Obesity

ArticleYear
Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
    Kidney international. Supplement, 2005, Issue:93

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diabetes Mellit

2005
Selective imidazoline agonist moxonidine in obese hypertensive patients.
    International journal of clinical practice, 2006, Volume: 60, Issue:5

    Topics: Adult; Amlodipine; Anthropometry; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio

2006
The effect of moxonidine on endothelial dysfunction in metabolic syndrome.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:5

    Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Caloric Restriction; Combined Modality

2006
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:7

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland

2007
Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1999, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat

1999

Other Studies

15 other studies available for moxonidine and Obesity

ArticleYear
[Obesity and hypertension. A dangerous liaison].
    MMW Fortschritte der Medizin, 2002, Oct-24, Volume: 144, Issue:43

    Topics: Antihypertensive Agents; Humans; Hypertension; Imidazoles; Obesity; Sympatholytics

2002
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:2

    Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Clonidine; Disease Models, Animal; Female; Glucose

2003
Cardiac effects of moxonidine in spontaneously hypertensive obese rats.
    Annals of the New York Academy of Sciences, 2003, Volume: 1009

    Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Female; Heart Atria; He

2003
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X.
    Annals of the New York Academy of Sciences, 2003, Volume: 1009

    Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Benzofurans; Blood Pressure; Disease

2003
Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Journal of human hypertension, 2004, Volume: 18, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure;

2004
Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 320, Issue:2

    Topics: Adipocytes; Animals; Dose-Response Relationship, Drug; Female; Glucose; Hypertension; Imidazoles; In

2007
Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:6

    Topics: Acetylcholine; Amlodipine; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, Wester

2007
Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target?
    Medical hypotheses, 1995, Volume: 44, Issue:3

    Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Catecholamines; Energy Intake; Energy Met

1995
Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
    Cardiovascular drugs and therapy, 1996, Volume: 10 Suppl 1

    Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Eating; Female; Glucos

1996
Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
    Hypertension (Dallas, Tex. : 1979), 1997, Volume: 30, Issue:6

    Topics: Animals; Antihypertensive Agents; Biological Transport; Blood Glucose; Body Weight; Fatty Acids, Non

1997
[The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
    Deutsche medizinische Wochenschrift (1946), 1998, Aug-14, Volume: 123, Issue:33 Suppl

    Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Imidazoles; Imidazoline Re

1998
Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:1

    Topics: Animals; Antihypertensive Agents; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Hypert

1999
Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
    Blood pressure. Supplement, 1998, Volume: 3

    Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Female; Hyperglycemia; Hypertension; Hypog

1998
The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones.
    British journal of pharmacology, 1999, Volume: 127, Issue:1

    Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Body Weight; C

1999
Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
    Annals of the New York Academy of Sciences, 1999, Nov-18, Volume: 892

    Topics: Animals; Anti-Obesity Agents; Carrier Proteins; Disease Models, Animal; Endocrine System; Female; Hy

1999